AI chipmaker Nvidia (NVDA) is out with its fourth quarter results after Wednesday's close, reporting adjusted earnings (S1.62 per share vs. estimates of $1.53) and revenue ($68.1 billion vs. estimates of $65.91 billion) that came out above Wall Street expectations. Nvidia's stock gets a lift in after-hours trading following this release. Yahoo Finance Tech Editor Dan Howley helps Market Domination...
AI chipmaker Nvidia (NVDA) is out with its fourth quarter results after Wednesday's close, reporting adjusted earnings (S1.62 per share vs. estimates of $1.53) and revenue ($68.1 billion vs. estimates of $65.91 billion) that came out above Wall Street expectations. Nvidia's stock gets a lift in after-hours trading following this release. Yahoo Finance Tech Editor Dan Howley helps Market Domination Overtime Host Josh Lipton dive into the company's earnings release and outlook forecasts. CFRA Research senior vice president and equity analyst Angelo Zino and Moor Insights & Strategy founder, CEO, and chief analyst Patrick Moorhead also come on the program to react to the earnings figures and the chip company's sales to China. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.
Honest Company press release ( HNST ): Q4 GAAP EPS of -$0.21 misses by $0.23 . Revenue of $88.04M (-11.8% Y/Y) misses by $0.53M . Revenue $306 million to $312 million range (or -18% to -16% compared to prior year) Organic Revenue Growth (1) 4% to 6% Adjusted Gross Margin Low 40%s Adjusted EBITDA (2) $20 million to $23 million range Click to enlarge More on Honest Company The Honest Company: Reorga...
Honest Company press release ( HNST ): Q4 GAAP EPS of -$0.21 misses by $0.23 . Revenue of $88.04M (-11.8% Y/Y) misses by $0.53M . Revenue $306 million to $312 million range (or -18% to -16% compared to prior year) Organic Revenue Growth (1) 4% to 6% Adjusted Gross Margin Low 40%s Adjusted EBITDA (2) $20 million to $23 million range Click to enlarge More on Honest Company The Honest Company: Reorganization Brings Efficiency, Not Growth Honest Company Q4 2025 Earnings Preview Central Garden and Honest Company fall after JPMorgan warns on the earnings setup Seeking Alpha’s Quant Rating on Honest Company Historical earnings data for Honest Company
Earnings Call Insights: LivaNova PLC (LIVN) Q4 2025 Management View CEO Vladimir Makatsaria highlighted that "2025 was a year of strong performance for LivaNova. We delivered double-digit revenue growth, meaningful adjusted operating margin expansion and robust cash generation, reflecting strong execution across our cardiopulmonary and epilepsy businesses." He emphasized the company's fifth consec...
Earnings Call Insights: LivaNova PLC (LIVN) Q4 2025 Management View CEO Vladimir Makatsaria highlighted that "2025 was a year of strong performance for LivaNova. We delivered double-digit revenue growth, meaningful adjusted operating margin expansion and robust cash generation, reflecting strong execution across our cardiopulmonary and epilepsy businesses." He emphasized the company's fifth consecutive year of double-digit EPS growth and the third year of double-digit organic revenue growth. CEO Makatsaria cited strategic progress, particularly the company’s entry into the obstructive sleep apnea (OSA) market, stating, "The first stage of that next chapter is obstructive sleep apnea, where we have a clear right to win based on rigorous clinical evidence, a differentiated technology designed to treat a broader range of challenging patients and our existing neuromodulation capabilities." CEO Makatsaria also announced a key leadership addition: "We recently appointed Lucile Blaise as Global Head of Commercialization for obstructive sleep apnea, further strengthening our leadership team as we prepare to scale the opportunity." CFO Alex Shvartsburg stated, "Revenue in the quarter was $361 million, an increase of 9.5% on a constant currency and organic basis versus the prior year." He added, "Adjusted diluted earnings per share was $0.86 compared to $0.81 in the fourth quarter of 2024." CFO Shvartsburg explained, "Q4 2025 included approximately $0.04 of favorable impact versus prior guidance assumptions related to cardiopulmonary investments, primarily due to timing of the Essenz printed circuit board conversion, where the related costs have been rephased over the rollout period." Outlook CEO Makatsaria guided for "full year 2026 revenue growth between 6% and 7%, which is consistent with the 2025 to 2028 framework detailed at our Investor Day." For cardiopulmonary, "we expect cardiopulmonary revenue to grow 7% to 8%." For epilepsy, "we expect epilepsy revenue growth of 5....
Crescent Energy Company press release ( CRGY ): Q4 GAAP EPS of -$0.03 misses by $0.20 . Revenue of $865.04M (-1.2% Y/Y) misses by $18.31M . More on Crescent Energy Company Crescent Energy: Vital Energy Acquisition Closes Crescent Energy: A Successful Example Of Divestitures And New Acquisitions Crescent Energy Company Q4 2025 Earnings Preview Crescent Energy sells non-operated DJ Basin assets in $...
Crescent Energy Company press release ( CRGY ): Q4 GAAP EPS of -$0.03 misses by $0.20 . Revenue of $865.04M (-1.2% Y/Y) misses by $18.31M . More on Crescent Energy Company Crescent Energy: Vital Energy Acquisition Closes Crescent Energy: A Successful Example Of Divestitures And New Acquisitions Crescent Energy Company Q4 2025 Earnings Preview Crescent Energy sells non-operated DJ Basin assets in $90M deal Seeking Alpha’s Quant Rating on Crescent Energy Company
Pursuit Attractions and Hospitality press release ( PRSU ): Q4 Non-GAAP EPS of -$0.89 misses by $0.09 . Revenue of $57.07M (-84.4% Y/Y) misses by $1.21M . Shares -3.94% AH. More on Pursuit Attractions and Hospitality Pursuit Attractions & Hospitality makes a strategic licensing move with its Flyover business Seeking Alpha’s Quant Rating on Pursuit Attractions and Hospitality Historical earnings da...
Pursuit Attractions and Hospitality press release ( PRSU ): Q4 Non-GAAP EPS of -$0.89 misses by $0.09 . Revenue of $57.07M (-84.4% Y/Y) misses by $1.21M . Shares -3.94% AH. More on Pursuit Attractions and Hospitality Pursuit Attractions & Hospitality makes a strategic licensing move with its Flyover business Seeking Alpha’s Quant Rating on Pursuit Attractions and Hospitality Historical earnings data for Pursuit Attractions and Hospitality Financial information for Pursuit Attractions and Hospitality
Procept press release ( PRCT ): Q4 GAAP EPS of -$0.53 misses by $0.20 . Revenue of $76.4M (+12.0% Y/Y) misses by $17.3M . Full Year 2026 Financial Guidance The Company expects revenue for the full year 2026 to be in the range of $390 million to $410 million, which represents growth of 27% to 33% compared to the prior year period The Company expects full year 2026 U.S. procedure growth to be in the...
Procept press release ( PRCT ): Q4 GAAP EPS of -$0.53 misses by $0.20 . Revenue of $76.4M (+12.0% Y/Y) misses by $17.3M . Full Year 2026 Financial Guidance The Company expects revenue for the full year 2026 to be in the range of $390 million to $410 million, which represents growth of 27% to 33% compared to the prior year period The Company expects full year 2026 U.S. procedure growth to be in the range of 39% to 48% compared to the prior year period The Company expects full year 2026 gross margin to be approximately 65% The Company expects full year 2026 operating expenses to be approximately $350 million The Company expects full year 2026 adjusted EBITDA* loss to be in the range of $30 million to $17 million First Quarter 2026 Financial Guidance The Company expects total procedures for the first quarter of 2026 to be in the range of 12,000 to 12,800, which represents growth of 31% to 36% compared to the prior year period. Total revenue for the first quarter of 2026 is expected to be in the range of $79 million to $82 million dollars, which represents growth of 14% to 19% to the prior year period. More on Procept PROCEPT BioRobotics Corporation (PRCT) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript Seeking Alpha’s Quant Rating on Procept Historical earnings data for Procept Financial information for Procept
Samsung’s Galaxy S26 phones introduce a slate of new AI-powered features, including some new photography tools. | Image: Samsung Samsung has just announced its new Galaxy S26 lineup , which includes the S26, S26 Plus, and S26 Ultra. While they aren't radical departures from last year's models, they bring a handful of notable upgrades. All three run on Qualcomm's Galaxy-centric Snapdragon 8 Elite G...
Samsung’s Galaxy S26 phones introduce a slate of new AI-powered features, including some new photography tools. | Image: Samsung Samsung has just announced its new Galaxy S26 lineup , which includes the S26, S26 Plus, and S26 Ultra. While they aren't radical departures from last year's models, they bring a handful of notable upgrades. All three run on Qualcomm's Galaxy-centric Snapdragon 8 Elite Gen 5, which delivers improved performance and powers a slew of new AI-based features. This includes the ability to screen unknown calls and edit photos by typing what you want changed, along with an update to Google Gemini that can carry out certain tasks in supported third-party apps, like Uber and DoorDash, on your behalf. Starting at $899.99, the S26 is the smallest and mo … Read the full story at The Verge.
Check out the companies making headlines in after-hours trading. Nvidia — Nvidia reported strong earnings and revenue for the fiscal fourth-quarter , leading shares to add more than 1% in extended trading. Nvidia reported adjusted earnings of $1.62 per share, while analysts expected $1.53 per share, according to LSEG. The chipmaker's revenue of $68.13 billion for the period also exceeded the $66.2...
Check out the companies making headlines in after-hours trading. Nvidia — Nvidia reported strong earnings and revenue for the fiscal fourth-quarter , leading shares to add more than 1% in extended trading. Nvidia reported adjusted earnings of $1.62 per share, while analysts expected $1.53 per share, according to LSEG. The chipmaker's revenue of $68.13 billion for the period also exceeded the $66.21 billion estimated, driven by significant growth in its core data center business. Snowflake – Shares of the software company slipped more than 2%. Snowflake said that its first-quarter product revenue would range between $1.262 billion and $1.267 billion, just slightly higher than the FactSet consensus call for $1.26 billion. Trade Desk — Shares of the advertising tech company plunged about 16% after Trade Desk called for first-quarter adjusted EBITDA, or earnings before interest, taxes, depreciation, and amortization, of roughly $195 million, falling significantly short of the $223 million expected from analysts polled by FactSet. Trade Desk also missed on first-quarter revenue projections, but its fourth-quarter results beat the Street's estimates. Synopsys — The electronic design automation company fell nearly 2% after full-year revenue guidance failed to impress Wall Street. Synopsys sees revenue ranging between $9.56 billion and $9.66 billion, while the LSEG consensus estimates called for $9.63 billion. Salesforce — Shares of the customer service software maker fell about 5% in the after-hours session. Salesforce provided fiscal 2027 revenue guidance ranging from $45.8 billion to $46.2 billion, while the FactSet consensus called for $46.11 billion. Fourth-quarter results surpassed expectations on the top and bottom lines , however. Nutanix — The cloud software company saw its shares pop 17%. Nutanix and AMD announced a multi-year partnership to jointly develop an artificial intelligence infrastructure platform. As part of this agreement, AMD will make a strategic inv...
Recursion Pharmaceuticals (NASDAQ:RXRX) used its latest earnings call to emphasize what management described as an inflection point for the company, highlighting a first positive clinical proof-of-concept in familial adenomatous polyposis (FAP), continued progress in partnerships—most notably a fift
Recursion Pharmaceuticals (NASDAQ:RXRX) used its latest earnings call to emphasize what management described as an inflection point for the company, highlighting a first positive clinical proof-of-concept in familial adenomatous polyposis (FAP), continued progress in partnerships—most notably a fift
MONTRÉAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSX-V: PHA ) (the “ Company ”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial Statements and MD&A for its first quarter ended December 31, 2025.
MONTRÉAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSX-V: PHA ) (the “ Company ”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial Statements and MD&A for its first quarter ended December 31, 2025.
filo Agilent ( A ) is down ~3% in after-hours trading as its fiscal 2026 Q1 results missed on both lines. However, it raised its EPS guidance for the year. FY26 non-GAAP EPS is now seen at $5.90-6.04, up from $5.86-$6.00. Consensus is $5.93. Agilent also raised the upper range of its revenue outlook to $7.3B-$7.5B from $7.3B-$7.4B before. Consensus is $7.36B. Q1 non-GAAP EPS of $1.36 compares to $...
filo Agilent ( A ) is down ~3% in after-hours trading as its fiscal 2026 Q1 results missed on both lines. However, it raised its EPS guidance for the year. FY26 non-GAAP EPS is now seen at $5.90-6.04, up from $5.86-$6.00. Consensus is $5.93. Agilent also raised the upper range of its revenue outlook to $7.3B-$7.5B from $7.3B-$7.4B before. Consensus is $7.36B. Q1 non-GAAP EPS of $1.36 compares to $1.31 in the year-ago period. Agilent was hurt in the quarter by year-over-year operating margin percentage declines in two of its three segments: l ife sciences and diagnostics markets and Agilent CrossLab. The company ended the quarter (Jan. 31) with cash and cash equivalents of ~$1.76B compared to ~$1.79B on Oct. 31, 2025. More on Agilent Technologies Agilent Technologies, Inc. (A) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Agilent Technologies, Inc. (A) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Agilent Technologies, Inc. (A) Presents at Citi Annual Global Healthcare Conference 2025 Transcript Agilent Technologies Non-GAAP EPS of $1.36 misses by $0.01, revenue of $1.8B misses by $10M Agilent Technologies Q1 2026 Earnings Preview